WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Regulatory Guidance forDeveloping Technologies.

Our attorneys bring deep healthcare and FDA regulatory knowledge to the questions that arise as technology reshapes how care is delivered, how health data moves, and how products reach the market.

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us
Quick Links
  • Visit our Careers Microsite
  • Find the right attorney
  • Sign in to Neuron

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

  • Attorney Recruiting
  • Professional Staff
  • Contacts

News and Featured Insights

Alerts
Major EU Consumer Law Reform for Online Businesses: European Commission Proposes Digital Fairness Act
News Articles
Wilson Sonsini Partners Sachin Kohli and Demian Ahn Contribute to Diligent’s Q4 GC Risk Index Report
Alerts
Delaware Corporation Law Council Proposes Amendments on Stockholder Proposals
Leading Matters
Client Highlights
Wilson Sonsini Advises Galvanize Therapeutics on Oversubscribed $130 Million Series D
On November 16, 2026, Galvanize Therapeutics®, a commercial-stage company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease, announced the closing of an oversubscribed $130 million Series D financing. Wilson Sonsini Goodrich & Rosati advised Galvanize Therapeutics® on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Fractile on $720 Million Series C
On November 11, 2026, Fractile, a chip-first frontier AI company, announced the completion of a $720 million Series C financing led by Thrive Capital, Founders Fund, Lightspeed, and Redpoint. CapitalG, DST Global, Elad Gil, BlackRock, Bain Capital Ventures (BCV), T. Rowe Price, SV Angel, Sovereign AI, British Business Bank, Shopify Ventures, Felicis, Gigascale Capital, 20VC, Georgian, and Balderton, as well as other existing investors,​ also participated in the round. Wilson Sonsini Goodrich & Rosati advised Fractile on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Frontage Holdings on Privatization and Asset Restructuring
On November 9, 2026, Frontage Holdings Corporation (Frontage) announced that it has entered into an agreement for (i) a privatization by way of scheme of arrangement through SanRex Limited, the offeror held by an investor consortium, and (ii) a subsequent asset restructuring (together, “the transaction”). Wilson Sonsini Goodrich & Rosati advised Frontage on the transaction.

Upon completion of the privatization, Frontage will become a wholly owned subsidiary of SanRex Limited. As part of the asset restructuring, Frontage’s business is expected to be divided among members of an investor consortium comprising Charles River Laboratories International, Inc. (expected to own and operate Frontage’s Exton, Pennsylvania-based bioanalysis and drug metabolism and pharmacokinetics (DMPK) business); a wholly owned subsidiary of Hangzhou Tigermed Consulting Co., Ltd., Frontage's controlling shareholder (expected to own and operate Frontage’s PRC-based business and the business currently owned and operated by Acme Bioscience, Inc. and/or its subsidiaries); and Dr. Song Li, chairman of Frontage's board of directors (expected to own and operate Frontage’s remaining business outside of the PRC). The transaction remains subject to shareholder and regulatory approvals.

Frontage is engaged in the provision of research, analytical, and development services throughout the product discovery and development continuum. Frontage provides integrated, scientifically driven support that enables biopharmaceutical and life science companies to achieve their product development goals.

The Wilson Sonsini team that advised Frontage on the transaction includes Yang Chu, Jie Zhu, Nicole Yuen, Yang Liao, Shuhan Zhang, Yuan Dong, and Yingqi Gu.

For more information, please refer to Frontage’s press release and the HKEX announcement.
Learn More
Client Highlights
Wilson Sonsini Advises Crosspoint Capital on Kindo's $30 Million Financing
On November 12, 2026, Kindo, an AI agent management platform, announced a $30 million raise co-led by Crosspoint Capital and Forgepoint Capital, bringing total funding to $57.6 million. TFX Capital and CircleRock Capital joined, alongside existing investors. Wilson Sonsini Goodrich & Rosati advised Crosspoint Capital on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Delix Therapeutics on IP Matters Related to $100 Million Series C Financing
On November 9, 2026, Delix Therapeutics (Delix), a clinical-stage neuroscience company pioneering the discovery and development of neuroplastogens, announced the closing of an oversubscribed $100 million Series C financing. The round was led by Johnson & Johnson Innovation – JJDC, Inc., the corporate venture capital organization of Johnson & Johnson, and SV Health Investors’ Dementia Discovery Fund, with participation from existing investors including RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital, as well as new investors, including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures, among others. Wilson Sonsini Goodrich & Rosati advised Delix on the intellectual property matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises PacBio on $100 Million At-the-Market Stock Offering
On November 10, 2026, Pacific Biosciences of California, Inc. (PacBio), developer of the world’s most advanced sequencing technologies, entered into a sales agreement with Allen & Company LLC to offer up to $100 million of its common stock through an at-the-market program. Under the terms of the agreement, PacBio may offer and sell shares of its common stock having an aggregate offering price of up to $100 million from time to time through or to Allen & Company LLC, acting as PacBio’s sales agent or principal. Wilson Sonsini Goodrich & Rosati advised PacBio on the transaction.

PacBio intends to use the proceeds from this offering, together with existing cash, cash equivalents, and investments, for research and development and working capital and general corporate purposes.

The Wilson Sonsini team that advised PacBio on the transaction included Andrew Hoffman, Zachary Myers, Annie Giomi, James Keegan, and Mounika Yepuri.

For more information, please see PacBio’s prospectus supplement.
Learn More
See More Leading Matters
The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.

Read More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Cookie Settings
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.